CMOH-01 is under clinical development by Curatis and currently in Phase II for Neuropathic Pain (Neuralgia). According to GlobalData, Phase II drugs for Neuropathic Pain (Neuralgia) have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CMOH-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
C-MOH-01 is under development for the treatment of medication overuse headache. It is a repurposed drug candidate. The drug candidate was also under development for the treatment of tension-type headache.
Curatis is a healthcare services provider. Established in 2002, it is headquartered in Switzerland.
For a complete picture of CMOH-01’s drug-specific PTSR and LoA scores, buy the report here.